Equities researchers at StockNews.com assumed coverage on shares of Accelerate Diagnostics (NASDAQ:AXDX – Get Free Report) in a research note issued on Monday. The firm set a “hold” rating on the medical research company’s stock.
Separately, BTIG Research upgraded shares of Accelerate Diagnostics to a “strong-buy” rating in a research report on Wednesday, December 11th.
Read Our Latest Report on Accelerate Diagnostics
Accelerate Diagnostics Stock Down 4.5 %
Insider Activity at Accelerate Diagnostics
In other Accelerate Diagnostics news, Director John Patience purchased 200,000 shares of Accelerate Diagnostics stock in a transaction that occurred on Tuesday, December 3rd. The stock was purchased at an average price of $1.57 per share, for a total transaction of $314,000.00. Following the transaction, the director now directly owns 653,224 shares in the company, valued at $1,025,561.68. This trade represents a 44.13 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. 43.60% of the stock is owned by insiders.
Hedge Funds Weigh In On Accelerate Diagnostics
A hedge fund recently bought a new stake in Accelerate Diagnostics stock. Y Intercept Hong Kong Ltd acquired a new position in shares of Accelerate Diagnostics, Inc. (NASDAQ:AXDX – Free Report) in the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 19,866 shares of the medical research company’s stock, valued at approximately $34,000. Y Intercept Hong Kong Ltd owned about 0.08% of Accelerate Diagnostics as of its most recent filing with the SEC. Institutional investors own 17.14% of the company’s stock.
About Accelerate Diagnostics
Accelerate Diagnostics, Inc, an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms.
Featured Stories
- Five stocks we like better than Accelerate Diagnostics
- Dividend King Proctor & Gamble Is A Buy On Post-Earnings Weakness
- Earn High Dividends With 2 Top REITs Set to Perform in 2025
- How to Read Stock Charts for Beginners
- Oilfield Leader SLB: An AI Name You Need to Know
- 3 Warren Buffett Stocks to Buy Now
- Top ETFs That Beat the Market in 2024 and Could Do It Again
Receive News & Ratings for Accelerate Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accelerate Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.